Genolution

Genolution Intangible Assets

The Intangible Assets of Genolution (225220.KQ) as of Oct 22, 2026 is 344.20 M KRW. In the previous year, Intangible Assets was 342.77 M KRW — a change of 0.42% (higher).

Intangible Assets

344.20 MKRW

YoY

0.42%

Last updated:

Intangible Assets of Genolution is 2024 344.20 M KRW. Intangible Assets of Genolution was 2023 342.77 M KRW. It decreases by 0.42% higher compared to the previous year.

The Genolution Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
581.00 M KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
851.00 M KRW
Jan 1, 2021
875.75 M KRW
Jan 1, 2022
437.83 M KRW
Jan 1, 2023
342.77 M KRW
Jan 1, 2024
344.20 M KRW
The Genolution Intangible Assets history
YEARIntangible AssetsYoY
344.20 MKRW+0.42%
342.77 MKRW-21.71%
437.83 MKRW-50.00%
875.75 MKRW+2.91%
851.00 MKRW—
0.00KRW—
0.00KRW-100.00%
581.00 MKRW+32.05%
440.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Intangible Assets of Genolution is 344.20 M KRW in 2024.

Intangible Assets of Genolution changed from 342.77 M KRW to 344.20 M KRW, representing a 0.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Genolution since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genolution

All Key Metrics — Genolution